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first symptoms or reduced lung function in childhood.
Objective: We investigated whether replicated genes for COPD
associate with transient early wheeze (TEW) and lung function
levels in 6- to 8-year-old children and whether cigarette smoke
exposure in utero and after birth (environmental tobacco smoke
[ETS]) modifies these effects.
Methods: The association of COPD-related genotypes of 20
single nucleotide polymorphisms in 15 genes with TEW, FEV1,
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68Results: AGER showed replicated association with FEV1/FVC
ratio.TNS1 associatedwithmoreTEWinPIAMAand lowerFEV1
in ALSPAC. TNS1 interacted with ETS in PIAMA, showing lower
FEV1 in exposed children. HHIP rs1828591 interacted with
cigarette smoke exposure in utero in PIAMA and with ETS in
ALSPAC, with lower lung function in nonexposed children.
SERPINE2, FAM13A, andMMP12 associated with higher FEV1
and FVC, and SERPINE2, HHIP, and TGFB1 interacted with
cigarette smoke exposure in utero inPIAMAonly, showingadverse
effects of exposure on FEV1 being limited to children with
genotypes conferring the lowest risk of COPD.
Conclusion: Our findings indicate relevant involvement of at
least 3 COPD genes in lung development and lung growth by
demonstrating associations pointing toward reduced airway
caliber in early childhood. Furthermore, our results suggest that
COPD genes are involved in the infant’s lung response to smoke
exposure in utero and in early life. (J Allergy Clin Immunol
2014;133:68-76.)
Key words: Chronic obstructive pulmonary disease, transient early
wheeze, lung function growth, in utero exposure
More than 30 years ago, Burrows suggested that disturbed early
development of the lungs might underlie the susceptibility to
chronic obstructive pulmonary disease (COPD), a hypothesis that
has recently been put forward again by several researchers.1-3
There is suggestive epidemiologic evidence that early-life events
program a child to be at increased risk for future COPD develop-
ment.4 Oxidant pollutants have been shown to influence both lung
development in utero and growth andmaturation of the lungs after
birth.5 Additionally, in utero exposure to maternal tobacco smoke
results in deficits in lung function measured soon after birth,
which can persist from childhood to adult life.6 Postnatal exposure
to tobacco smoke might have an additional adverse effect on lung
growth, although conflicting findings have been reported.7,8
COPD can have not only its origins but also its first signs and
symptoms in early childhood, which might offer opportunities for
early identification of subjects susceptible to COPD. Several
studies have shown that an early-life history of respiratory disease
increases the mortality caused by COPD.2,9 Especially the occur-
rence of transient early wheeze (TEW) in childhood can consti-
tute a first sign of disturbed early lung development and lung
growth because TEW has been shown to associate with reduced
lung function already soon after birth, which is probably caused
by genetic constitution, in utero exposures (eg, cigarette smoke),
or both.10 Furthermore, these airway developmental abnormali-
ties related to TEW have been shown to associate with lower
lung function when symptoms have disappeared, which then
J ALLERGY CLIN IMMUNOL
VOLUME 133, NUMBER 1
KERKHOF ET AL 69Abbreviations usedTA
No
Ma
Mo
Fat
Mo
ET
Old
Da
Pre
Du
N
<
>
Mo
L
I
H
Wh
N
T
FE
FV
FE
ValALSPAC: ABLE I. Ch
. genotyped
le sex
ther allerg
her allergic
ther smoki
S exposure
er siblings
y care atten
mature bir
ration of b
ever
3 mo
_3 mo
ther’s educ
ow
ntermediat
igh
eezing phe
ever whee
EW
V1 (% pred
C (% pred
V1/FVC (%
ues are presevon Longitudinal Study of Parents and ChildrenCOPD: Chronic obstructive pulmonary diseaseETS: Environmental tobacco smokeFVC: Forced vital capacityKOALA: Child, parents and health: lifestyle and genetic constitutionOR: Odds ratioPIAMA: Prevention and Incidence of Asthma and Mite AllergyRAGE: Receptor for advanced glycation end productsSNP: Single nucleotide polymorphismTEW: Transient early wheezepersists through the rest of childhood and adolescence.11-14 Hence
TEWmight relate to later development of COPD. Our hypothesis
is that COPD genes influence structural and functional airway de-
velopment in utero and hence the occurrence of TEWand that the
presence of TEW might be a forerunner of a lifelong lower-than-
average lung function in a subset of children, eventually predis-
posing them to COPD.
Amajor limiting factor in research on the hypothesis that COPD
has its origins in early childhood is the huge logistic difficulty of
studying the effect of early-life eventswith respect to a disorder that
only becomes apparent 50 to 60 years later. Therefore research
must rely on indirect evidence, which can be obtained by inves-
tigating potential common underlying genes. We have previously
published data connecting genes that are important for lunggrowth,
such as ADAM33, with susceptibility to COPD.15,16 We here show
our investigation into whether replicated genes associated with
COPD are additionally associated with TEW, the phenotype that
is most relevant to our hypothesis, because it is characterized by
a reduced lung function in later childhood, as well as with the level
of lung function in children in the Prevention and Incidence of
Asthma and Mite Allergy (PIAMA) birth cohort and replicatedaracteristics of the birth cohorts
PIAMA
1996
51.6 (1030)
ic 37.5 (749)
30.8 (615)
ng during pregnancy 12.0 (240)
in first year 25.0 (477)
at birth 51.7 (927)
dance 24.6 (489)
th 4.6 (91)
reast-feeding
15.7 (311)
35.6 (706)
48.7 (967)
ational level
20.0 (398)
e 42.3 (842)
37.7 (751)
notypes
ze 60.2 (1132)
22.8 (429)
icted), mean 6 SD (n) 104.0 6 10.8 (914
icted), mean 6 SD (n) 102.7 6 10.9 (914
predicted), mean 6 SD (n) 97.6 6 7.1 (914)
nted as percentages (numbers) or means 6 SDs (numbers).significant associations in the KOALA and Avon Longitudinal
Study of Parents and Children (ALSPAC) cohorts.METHODS
Study populations
The PIAMA, KOALA, and ALSPAC birth cohorts have been described in
detail elsewhere.17-19 A description of the selection of the study populations is
provided in the Methods section in this article’s Online Repository at www.
jacionline.org. Children with a mother of non-Dutch origin were excluded
from the analyses.
Complete data on spirometry and genotypes were available for 914 PIAMA
children, 366 KOALA children, and 4851 ALSPAC children (Table I).Single nucleotide polymorphism selection and
genotyping
We searched the literature up to March 2010 and selected 21 single
nucleotide polymorphisms (SNPs) fulfilling 1 or more of the following criteria
in white populations:
1. Replicated SNPs from genome-wide association studies on COPD,
FEV1, or FEV1/forced vital capacity (FVC) ratio;
2. SNPs significantly associated with COPD in a published meta-analy-
sis20; and
3. SNPs published to show significant association with COPD in 3 or
more independent populations.
We selected SNPs in the following 15 genes: SFTPB,21 TNS1,22
SERPINE2,23,24 FAM13A,25 GSTCD,22,26 HHIP,26-28 ANKH,28 HTR4,22
AGER,22,26 MMP12,29 THSD4,22 IREB2,30 AGPHD1,28 CHRNA3,28 and
TGFB1.20 SNP (rs1800470) in the TGFB1 gene failed genotyping. The 20 an-
alyzed SNPs are shown in Table II.20-30 Genotyping methods and patterns of
linkage disequilibrium (Table E1) within loci are described in the Methods
section in this article’s Online Repository. We have selected proxy-SNPs for
unavailable SNPs in ALSPAC by using HapMap release 2231: rs975278 in
SERPINE2 for rs729631 (r2 5 1) and rs6734100 (r2 5 0.82), rs17368659 in
MMP12 for rs2276109 (r25 1), and rs8109167 in TGFB1 for rs6957 (r25 1).KOALA ALSPAC
1572 4851
50.4 (792) 50.6 (2455)
32.9 (517) 47.7 (2220)
36.5 (562) 40.2 (1410)
4.4 (69) 19.6 (915)
11.4 (168) 34.7 (1210)
58.4 (901) 52.9 (2440)
35.4 (538) 11.1 (489)
3.7 (58) 5.0 (234)
14.7 (231) 17.7 (793)
20.7 (325) 30.6 (1375)
64.6 (1016) 51.8 (2326)
8.4 (126) 20.1 (949)
37.3 (561) 34.3 (1615)
54.4 (818) 45.6 (2151)
63.2 (773) 68.7 (2023)
22.2 (272) 31.3 (921)
) 96.4 6 11.5 (366) 98.3 6 11.7 (4851)
) 101.4 6 11.7 (366) 97.7 6 11.9 (4851)
92.0 6 6.7 (366) 99.9 6 7.3 (4851)
TABLE II. Characteristics of the selected SNPs
SNP Nearest gene Chromosome Position
Major >
minor allele
MAF
PIAMA
Risk
allele* Function Phenotype References
rs1130866 SFTPB 2 85893741 T>C 0.47 C Missense COPD Hersh et al21
rs2571445 TNS1 2 218683154 C>T 0.36 T Missense FEV1 Repapi et al
22
rs6734100 SERPINE2 2 224841995 C>G 0.13 C Intronic COPD DeMeo et al23 and
Zhu et al24
rs729631 SERPINE2 2 224844919 C>G 0.16 C Intronic COPD DeMeo et al23 and
Zhu et al24
rs7671167 FAM13A 4 89883979 T>C 0.46 T Intronic COPD Cho et al25
rs10516526 GSTCD 4 106908353 A>G 0.06 A Intronic FEV1 Repapi et al
22 and
Hancock et al26
rs1032295 HHIP 4 145654034 T>G 0.40 T Intergenic FEV1/FVC Hancock et al
26
rs1828591 HHIP 4 145700230 A>G 0.42 A Intergenic FEV1/FVC, COPD Wilk et al
27 and
Pillai et al28
rs9686327 ANKH 5 15071537 G>A 0.17 ? Intergenic COPD Pillai et al28
rs735243 ANKH 5 15092327 G>A 0.14 ? Intergenic COPD Pillai et al28
rs3995090 HTR4 5 147826008 A>C 0.44 A Intronic FEV1 Repapi et al
22
rs2070600 AGER 6 32151443 C>T 0.03 C Missense FEV1/FVC Hancock et al
26 and
Repapi et al22
rs2276109 MMP12 11 102745791 A>G 0.12 A 59UTR COPD, FEV1 Hunninghake et al
29
rs12899618 THSD4 15 71645120 G>A 0.17 A Intronic FEV1/FVC Repapi et al
22
rs2568494 IREB2 15 78740964 G>A 0.31 A Intronic COPD DeMeo et al30
rs2656069 IREB2 15 78745707 T>C 0.24 T Intronic COPD DeMeo et al30
rs8034191 AGPHD1 15 78806023 T>C 0.31 C Intronic COPD Pillai et al28
rs1051730 CHRNA3 15 78894339 C>T 0.31 T Exon: synonymous COPD Pillai et al28
rs6957 TGFB1 19 41830606 T>C 0.15 C 39UTR COPD Smolonska et al20
rs1800469 TGFB1 19 41860296 T>C 0.30 T Promoter COPD Smolonska et al20
MAF, Minor allele frequency (proportion); UTR, untranslated region.
*Allele with highest risk of COPD or lowest lung function level; ? 5 risk alleles are inconsistently associated with COPD.
TABLE III. Association of SNPs in known COPD genes with TEW, FEV1, FVC, and FEV1/FVC ratio in the PIAMA study
SNP Nearest gene Effect allele Genetic model Trait Effect (95% CI) P value
rs2571445 TNS1 T Additive TEW 1.24 (1.05 to 1.47) .014
rs6734100 SERPINE2 C Dominant FEV1 4.77 (0.25 to 9.29) .039
FVC 5.52 (0.92 to 10.1) .019
rs729631 SERPINE2 C Dominant FEV1 5.12 (0.93 to 9.30) .017
FVC 4.57 (0.34 to 8.81) .034
rs7671167 FAM13A T Recessive FEV1 2.02 (0.33 to 3.70) .019
FVC 2.33 (0.64 to 4.03) .007
rs1828591 HHIP A Additive TEW 1.27 (1.07 to 1.50) .005
rs2070600 AGER C Additive FEV1/FVC 22.52 (24.34 to 20.70) .007
rs2276109 MMP12 A Dominant FVC 11.21 (1.60 to 20.8) .022
Results are presented as ORs for TEW and as the mean difference in FEV1 or FVC percent predicted between children with and without the effect genotype.
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TEWwas defined as parentally reportedwheeze in the last 12months at age
1 or 2 years but not at age 4 and 6 years because KOALA only collected data at
these time points. Children without wheeze at ages 1, 2, 4, and 6 years served
as the reference group. FEV1 and FVC were measured at age 8 years in
PIAMA and ALSPAC and age 6 years in KOALA by using spirometry, with
themethods detailed in theMethods section in this article’s Online Repository.
Percent predicted FEV1, FVC, and the FEV1/FVC ratio were calculated ac-
cording to previously published prediction equations.32
Maternal smoking during pregnancy was defined as smoking by the mother
in the last trimester of pregnancy. Environmental tobacco smoke (ETS)
exposure in the first year was defined as smoking of any household member in
the house in PIAMA, smoking in the vicinity of the child in KOALA, and
parental smoking during the first year of the child’s life in ALSPAC.
Statistical analysis
Genetic association testing for each SNP separately was performed by
using a codominant (general) model. Only when the overall P value was lessthan .10 was the best fitting genetic model (dominant, recessive, or additive)
further explored. Logistic and linear regression analysis was performed by an-
alyzing TEW and lung function parameters as the outcome, respectively.
Gene–smoke exposure interactions were tested for significance (P < .05) by
including an interaction term in the regression models. The presence of rele-
vant confounding of the associations was evaluated by including variables
(day care attendance, the presence of older siblings, and sex) in the regression
model. No variables caused a greater than 10% change in coefficients. There-
forewe did not include any covariates in the presented models. These analyses
were performed in both PIAMA and KOALA. Results from KOALA are pre-
sented in theMethods section in this article’s Online Repository; because lung
function was available only in a small proportion of that population (n5 366),
we could not draw firm conclusions.
SNPs showing significant associations were tested for main associations or
interactions for all outcomes using imputed dosages, which would be
equivalent to additive genetic models in ALSPAC. Associations were
considered replicated when a significant effect in the same direction was
observed for any of the outcomes.
FIG 1. Box plot of FEV1/FVC percent predicted by genotype of AGER rs2070600 in PIAMA.
TABLE IV. Significant interaction of SNPs in COPD genes with maternal smoking during pregnancy or environmental smoke
exposure in the first year of life with respect to lung function parameters observed in PIAMA
SNP Nearest gene
Effect
allele
Genetic
model Trait
Effect (95% CI) of genotype on lung function (in presence or absence of exposure)
Maternal smoking during pregnancy Environmental smoke in first year
Yes No P-int Yes No P-int
rs2571445 TNS1 T Recessive FEV1 24.89
(29.18 to 20.60)
1.75
(20.94 to 4.44)
.010
rs729631 SERPINE2 C Recessive FVC 6.22
(1.35 to 11.1)
20.76
(22.52 to 1.00)
.008 2.98
(20.31 to 6.26)
21.16
(23.11 to 0.79)
.034
rs1032295 HHIP T Dominant FEV1 7.27
(1.46 to 13.1)
21.30
(23.48 to 0.87)
.007
FEV1/FVC 5.58
(1.76 to 9.39)
20.63
(22.06 to 0.79)
.003
rs1828591 HHIP A Dominant FEV1 5.48
(0.09 to 10.9)
22.58
(24.73 to 20.44)
.006
FEV1/FVC 4.46
(0.93 to 7.99)
21.68
(23.08 to 20.27)
.002
rs6957 TGFB1 C Dominant FEV1 5.51
(0.43 to 10.6)
20.63
(22.33 to 1.07)
.025
FVC 6.14
(1.02 to 11.3)
20.69
(22.41 to 1.03)
.013
Results are presented as the mean difference in FEV1 or FVC percent predicted between children with and without the effect genotype.
P-int, P value interaction term.
P < .05 (boldface).
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The characteristics of the populations are shown in Table I.
TEW was present in 23%, 22%, and 31% of the children from
PIAMA, KOALA, and ALSPAC, respectively. The mean FEV1
percent predicted was higher in PIAMA than in KOALA and
ALSPAC.
Main associations of COPD SNPs with TEW
The TNS1 SNP rs2571445 (odds ratio [OR] per allele, 1.24
[95% CI, 1.05 to 1.47]; P 5 .01) and the HHIP SNP rs1828591(OR per allele, 1.27 [95% CI, 1.07 to 1.50]; P 5 .005) were
significantly associated with TEW compared with the ‘‘never
wheeze’’ category in PIAMA.Main effects of COPD SNPs on childhood lung
function
SNPs in 4 genes were significantly associated with FEV1, FVC,
or FEV1/FVC ratio (Table III). Childrenwith 1 ormoreCOPD risk
alleles of the SERPINE2 SNPs or 2 risk alleles of the FAM13A
TABLE V. Effects of different combinations of genotype and exposure on outcomes for SNPs involved in the response to oxidative
stress significantly interacting with exposure
SNP
Nearest
gene Trait
Major >
minor COPD RA
Reference
genotype
(<_1 RA) Exposure
Reference genotype COPD genotype
Not
exposed Exposed Not exposed Exposed
rs2571445 TNS1 FEV1 C>T T CC/CT ETS Reference 0.55
(21.34 to 2.43)
1.75
(20.94 to 4.44)
24.34
(28.42 to 20.27)
rs729631 SERPINE2 FVC C>G C GG/GC IUS Reference 25.68
(210.0 to 21.33)
20.76
(22.52 to 1.00)
0.54
(22.49 to 3.57)
rs1032295 HHIP FEV1 T>G T GG IUS Reference 29.17
(214.8 to 23.51)
21.30
(23.48 to 0.87)
21.89
(25.03 to 1.24)
FEV1/FVC GG 26.67
(210.4 to 22.96)
20.63
(22.06 to 0.79)
21.09
(23.15 to 0.97)
rs1828591 HHIP FEV1 A>G A GG IUS Reference 28.75
(214.0 to 23.54)
22.58
(24.73 to 20.44)
23.27
(26.38 to 20.15)
FEV1/FVC GG 26.24
(29.65 to 22.83)
21.68
(23.08 to 20.27)
21.78
(23.82 to 0.26)
rs6957 TGFB1 FEV1 T>C C TT IUS Reference 23.73
(26.42 to 21.05)
20.63
(22.33 to 1.07)
1.77
(22.73 to 6.27)
FVC 22.03
(24.75 to 0.68)
20.69
(22.41 to 1.03)
4.10
(20.43 to 8.64)
Effect estimates (95% CIs) are presented for the specific combination compared with the reference group with 1 or fewer COPD risk alleles and without exposure calculated as ORs
for TEW and the mean difference in percent predicted FEV1, FVC, and FEV1/FVC.
IUS, Cigarette smoke exposure in utero; RA, risk allele.
P < .05 (boldface).
FIG 2. Box plots of FEV1 percent predicted for children without (RA2) or with (RA1) risk allele A ofHHIP SNP
rs1828591 in PIAMA stratified by exposure to maternal smoking during pregnancy.
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(Table III). Children with 1 or more COPD risk allele of
MMP12 SNP rs2276109 had a significantly higher mean FVC
than children without COPD risk alleles (Table III). A similar
nonsignificant effect of MMP12 was observed for FEV1.The FVC was higher and the FEV1/FVC ratio was
lower in children with a higher number of COPD risk
alleles of the AGER SNP rs2070600 (Fig 1, and Table III).
We found no association of the other genes with lung
function.
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Maternal smoking during pregnancy was not significantly
associated with TEW in PIAMA (OR, 1.1 [95% CI, 0.8 to 1.5];
P 5 .71). Mean FEV1 was significantly lower (22.3% [95% CI,
24.6% to 20.1%], P 5 .04) in exposed children than in nonex-
posed children. Maternal smoking during pregnancy was not
significantly associated with FVC (data not presented). ETS
exposure in the house was not significantly associated with
TEW or lung function levels. Associations of exposure with
outcomes for the replication cohorts are shown in the Results
section in this article’s Online Repository at www.jacionline.org.Effect modification by maternal smoking during
pregnancy
SNPs in 3 genes interacted significantly with exposure to
maternal smoking during pregnancy (Table IV). In utero exposure
was only associated with lung function in children without (HHIP
and TGFB1) or with zero or 1 (SERPINE2) COPD risk alleles
(Table V). As a result, COPD risk alleles of these genes were as-
sociated with better lung function in exposed children (Table IV).
The presence of 2 COPD risk alleles of SERPINE2 SNP rs729631
was significantly associated with a higher mean FVC only in chil-
dren exposed to maternal smoking during pregnancy (Table IV).
The presence of 1 or more COPD risk alleles of theHHIP SNPs
rs1032295 or rs1828591 was associated with a significantly
higher FEV1 and a higher FEV1/FVC ratio only in children whose
mother smoked during pregnancy (Table IV). In nonexposed chil-
dren a significant opposite effect was observed for rs1828591 (ie,
the presence of >_1 COPD risk allele was associated with lower
levels; Table IV). Both exposed and nonexposed children with
1 or more COPD risk alleles of rs1828591 had significantly lower
FEV1 levels than the reference group of nonexposed children
without COPD risk alleles (Table V). Fig 2 shows this by showing
the FEV1 levels for the 4 combinations of genotypes and expo-
sure. Exposure was significantly associated with lower FEV1
levels in children without risk alleles and not in children with
1 or more risk alleles of rs1828591.
The presence of COPD risk alleles of the TGFB1 SNP rs6957
was associated with higher FEV1 levels in children exposed to
smoke in utero as well but not in children without exposure.
A similar effect was found on FVC in children exposed to smoke
in utero.
We found no significant interaction of the SNPs with maternal
smoking during pregnancy in the association with TEW.Effect modification by tobacco smoke exposure
after birth
For the TNS1 SNP, significant interaction (P5 .03) with expo-
surewas observed, showing worse lung function levels in children
exposed to smoke in the home who had the genotype conferring a
higher risk of COPD (Table V). Childrenwith 2 COPD risk alleles
exposed to smoke had the lowest mean FEV1 percent predicted,
5% lower than children exposed to smoke without the risk geno-
type (Tables IV and V).
SERPINE2 SNP rs729631 significantly (P 5 .03) interacted
with smoke exposure in the association with FVC in PIAMA
(Table IV). ETS exposure was associated with a 6% lower FVC
percent predicted in children without the COPD-related genotype
(Table V).We found no significant interaction between the SNPs and
exposure to tobacco smoke in the first year of life in the
association with TEW.
Replication results
In the ALSPAC study significant associations with lung
function levels were found for 5 of the 7 associated COPD genes
(Table VI). The main association of the AGER SNP rs2070600
with FEV1/FVC ratiowas strictly replicated. The other significant
associations in ALSPAC were observed for different outcomes,
different genetic models, or different interacting exposures.
FEV1 decreased significantly with the number of COPD risk al-
leles of TNS1 in ALSPAC (Table VI). In PIAMA the risk of TEW
increasedwith the number of COPD risk alleles, whereas the pres-
ence of 2 COPD risk alleles in TNS1 associated with lower FEV1
levels in ETS-exposed children only (Tables IV and V).
The significant effects of SERPINE2 on FEV1 were opposite in
direction in ALSPAC (Table VI) compared with PIAMA (Table
III). The effect ofHHIP rs1828591 on FEV1 and FVCwas signif-
icantly modified by ETS exposure in the first year, with signifi-
cantly lower FVC levels with increasing COPD risk alleles in
ALSPAC children not exposed to ETS. In PIAMA effect modifi-
cation in the same direction on FEV1 and FEV1/FVC ratio was
observed for in utero smoke exposure.
For MMP12, a higher number of COPD risk alleles was asso-
ciatedwith a higher FEV1/FVC ratio in ALSPAC children in utero
exposed to smoke. In PIAMA the presence of 1 or 2 MMP12
COPD risk alleles associated with a higher FVC in the total
population.
None of the associations were replicated in KOALA (see the
Results section in this article’s Online Repository).
DISCUSSION
To our knowledge, this is the first study to test the hypothesis
that genetic variants known to be associated with COPD and
lower lung function in adults are associated with lung function
and/or TEW, amarker of low lung function in early childhood.We
found significant associations for 7 of the 15 genes in the PIAMA
cohort; this was very unlikely to have occurred by chance. For 5 of
these 7 genes, significant associations were observed with lung
function levels in the ALSPAC cohort as well. COPD risk alleles
of SNPs in TNS1, HHIP, and AGER pointed toward reduced air-
way caliber, as reflected by either TEW, lower FEV1, or lower
FEV1/FVC ratio in both PIAMA and ALSPAC. Conversely,
COPD risk alleles of SNPs in SERPINE2, FAM13A, and
MMP12 were associated with higher FEV1 and FVC in PIAMA,
results that were not replicated andmight be due to chance. More-
over, smoke exposure during pregnancy or early life significantly
interacted with effects of SNPs in TNS1, SERPINE2, HHIP,
MMP12, and TGFB1 in PIAMA and with HHIP and MMP12 in
ALSPAC. Thus our findings indicate relevant involvement of at
least 3 COPD genes in lung development and lung growth.
The results for TNS1 and AGER are most consistent with find-
ings in adults. Tensin 1 is involved in signal transduction and cell
migration.33 The TNS1 locus at 2q35 was initially discovered in a
genome-wide association study on FEV1.
22 The main hit
rs2571445, a nonsynonymous coding SNP, has recently been re-
ported to be associated with the presence of GOLD stage 2 to 4
COPD as well.33
Our findings on the AGER SNP rs2070600 affecting the FEV1/
FVC ratio are in line with the results from Hancock et al.26 The
TABLE VI. Replication results in the ALSPAC cohort
SNP Nearest gene Effect allele MAF Trait Mean difference per allele P value
rs2571445 TNS1 A4T A (0.40) FEV1 20.48 (20.96 to 20.01) .047
FVC 20.47 (20.96 to 0.01) .054
rs975278 (proxy) SERPINE2 C T (0.19) FEV1 20.72 (21.33 to 20.11) .021
rs1032295 HHIP T G (0.40) FEV1
FVC
rs1828591 HHIP A G (0.40) FEV1
FVC
rs2070600 AGER C T (0.07) FEV1/FVC 20.71 (21.27 to 20.16) .012
rs17368659 (proxy) MMP12 G T (0.13) FEV1/FVC
Results are presented as the mean difference in FEV1 or FVC percent predicted per effect allele (additive genetic model). Only results with P values of less than .10 are shown.
A4T, Genotyped on the opposite strand; MAF, minor allele frequency; P-int, P value interaction term.
J ALLERGY CLIN IMMUNOL
JANUARY 2014
74 KERKHOF ET ALpresence of 2 risk alleles of this nonsynonymous SNP in the gene
coding for the receptor for advanced glycation end products
(RAGE) has been reported to be strongly associated with higher
levels of soluble forms of this protein in a Dutch population.34
RAGE expression is most abundant in the lung, and the intensity
of expression in respiratory epithelial cells varies during lung
morphogenesis.35 It has been shown to play a role in critical pro-
cesses directly involved in perinatal transitioning of the embry-
onic lung into a mature functional organ.35
Hedgehog-interacting protein (HHIP) has been implicated in
organ development and repair in multiple tissues36 and is there-
fore a strong candidate gene for COPD. Our findings of HHIP
SNP rs1828591 risk alleles being associated with an increased
risk of TEW and lower lung function support our hypothesis.
In addition, we have made an intriguing observation that for
some genes exposure effects on lung function were only observed
in children without or with only 1 risk allele or alleles of genes
known to be associated with COPD.As a result, COPD risk alleles
of these genes were associated with better lung function in
exposed children. We have observed these effects in PIAMA for
SERPINE2, HHIP, and TGFB1, genes that are all strong candi-
dates for our hypothesis because they play an important role in
lung morphogenesis.1,23,37,38 A significant interaction in the
same direction was only replicated for HHIP in ALSPAC. There-
fore we cannot exclude that these findings are false positive. Fur-
ther research has to be performed because the exposure effects
were not minor. Adverse effects of 4% to 9% in FEV1 percent pre-
dicted with in utero exposure were observed in PIAMA children
without COPD-related genotypes. If these observations are repli-
cated in future studies and found for other genes replicated as
well, we put forward that this might be due to the fact that genetic
effects during lung development in utero might be different from
effects at adult age, where the lung has been fully developed and
effects might be targeting lung tissue destruction.
Our hypothesis was that COPD genes influence early lung
development, such as branching morphogenesis in utero, hence
showing an indirect relationship with TEW, a marker of lower
lung function. Alternatively, COPD genes might influence sus-
ceptibility to early-life respiratory tract infections leading to
TEW without a relationship with later COPD. However, we did
not observe a direct relationship of TNS1 and HHIP with the oc-
currence of lower respiratory tract infections in PIAMA (data notshown), making this alternative explanation of the association of
these genes with TEW unlikely.
Low lung function in childhood is not specific for COPD and
can also be caused by other diseases, such as bronchopulmonary
dysplasia, cystic fibrosis, and asthma.39 Furthermore, some of the
genes we have studied are associated not onlywith COPD but also
with asthma.40-42 We cannot fully exclude that observed associa-
tions with lung function in our birth cohort might be ascribed to
asthma. However, this is unlikely because none of the SNPs
were associated with doctor-diagnosed asthma at age 8 years
(data not shown). Our findings support the general concept of
the ‘‘Dutch hypothesis’’ by showing common genetic origins of
obstructive airway disease in childhood and COPD at older age
related to environmental pressure.4
Our aim was to detect all possible relevant associations of
variants in the 15 COPD genes with any of the outcome
parameters. We acknowledge that our strategy of avoiding
type II errors implies accepting a higher risk of type I errors.
We have calculated the probability of observing a P value as
small as our minimum P value under the null hypothesis of no
main associations to be 20%.43 Thus we cannot fully exclude
that some of the statistically significant test results observed in
the PIAMA study are false positive because of multiple testing.
Because the effect sizes we actually found were at a level that
would be very relevant, we evaluated our positive findings in
the larger ALSPAC cohort. We are convinced that we have
found evidence that at least some of the genes known to be in-
volved in COPD play a role in lung function development and
growth in childhood. Otherwise, it would be very unlikely to
find so many statistically significant associations. For example,
the probability to find 10 or more significant main associations
with any of the outcomes for the 20 SNPs by chance in PIAMA
would be only 0.7%. Further research on this topic has to be per-
formed to pinpoint the variants in the genes studied and the un-
derlying mechanisms.
Because our aimwas to link childhood lung function with adult
COPD, we have chosen to limit our study to SNPs previously
associated with COPD that mostly emerged from studies covering
the complete gene by haplotype tagging SNPs. Because of this
strategy, we cannot exclude that other functional genetic variants
in the genes that were not related to COPD associate with
childhood lung function or TEW.
Mean difference (95% CI) in lung function per COPD risk allele (in presence or absence of exposure)
Maternal smoking pregnancy ETS exposure first year
Yes No P-int Yes No P-int
20.93 (22.14 to 0.28) 0.29 (20.26 to 0.85) .065 20.91 (21.94 to 0.12) 0.33 (20.38 to 1.04) .047
20.44 (21.47 to 0.59) 0.66 (20.06 to 1.38) .082
0.68 (20.49 to 1.85) 20.40 (20.94 to 0.15) .095 0.92 (20.09 to 1.92) 20.37 (21.07 to 0.32) .036
0.50 (20.50 to 1.51) 20.73 (21.44 to 20.03) .046
1.12 (0.08 to 2.16) 20.52 (21.01 to 0.03) .005
TABLE VI. (Continued)
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lung function levels and occurrence of symptoms between
genotypes. For example, we had more than 90% statistical power
to find additive effects on FEV1 of 2% per allele in PIAMA chil-
dren at ana value of .05. However, a reasonwhy the findings from
the PIAMA study could not be replicated in KOALA could be that
the number of lung function measurements in KOALA was too
small to detect relatively small effects (<5%) under a recessive
mode of inheritance, as observed in PIAMA. Moreover, lung
function was measured at a younger age in KOALA, and we ob-
served many differences in characteristics between both studies
that might have played a role. The exceptionally low prevalence
of maternal smoking during pregnancy in the KOALA cohort
might have hampered the statistical power to find interactions
in this study.
Because KOALA did not collect data on the third year of life,
TEW could not be defined by using the standard definition of
wheeze in the first 3 years and not at age 6 years.11 However, the
results were not altered when using this definition in PIAMA or
when analyzing TEW as the outcome, which is one of the previ-
ously identified and validated phenotypes from longitudinal latent
class analysis in PIAMA (data not shown).44 In the analyses on
TEW we have excluded children with symptoms of wheeze at
school age (5.6% with late onset and 11.4% with persistent
wheeze in PIAMA), an outcome known to be closely related to
asthma and allergic sensitization.11 This might have affected
the results. However, analyses, including these children in the ref-
erence group produced similar results with significant ORs for
TNS 1 (OR, 1.23 [95% CI, 1.04 to 1.25]) and HHIP (OR, 1.33
[95% CI, 1.13 to 1.57]), showing the robustness of our findings.
A challenge to directly assess relationships between COPD
genes, early lung function deficits, and COPD is to overcome the
long time period between early childhood events and COPD
onset. This might require long-term follow-up or, alternatively,
well-documented historical data on relevant exposures and
wheeze history in retrospective cohorts or case-control studies
of COPD onset with genotyping of the relevant genes.
In summary, our results support the general hypothesis that
COPD has its origins in early childhood by demonstrating
associations between several important COPD-associated genes
and transient early symptoms of wheeze and lower lung function
in the PIAMA and ALSPAC studies. These effects were not
minor. Differences of 4% to 7% in FEV1 percent predictedbetween children with and without the COPD genotypes were ob-
served in PIAMA children exposed to maternal smoking during
pregnancy. Our results suggest that COPD genes are involved in
the infant’s lung response to maternal smoking during pregnancy.
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Study population: PIAMA
Recruitment of participants took place in 1996-1997 through 52 antenatal
clinics in 3 different regions: the north (Groningen and surroundings),
central (Utrecht and Wageningen), and southwest (Rotterdam) of The
Netherlands. A total of 4146 pregnant women were recruited from the
general population by using a validated short screening questionnaire, and
their children were followed from birth in 1996-1997. Children from
mothers reporting symptoms of allergic disease were defined as high risk.
All these 1327 children and a random sample of 663 children from
nonallergic mothers were selected for lung function measurements.
Spirometry was successfully performed in 1058 children at age 8 years.
Genotypes were obtained from 1996 children from PIAMA after exclusion
of 53 children from non-Dutch mothers. Complete data on genotypes and
spirometry were available from 914 children.
The medical ethics committees approved the study, and all participants
provided written informed (parental) consent.
Study population: KOALA
For the KOALA birth cohort, 2343 children from healthy pregnant women
were recruited in weeks 10 to 14 of pregnancy from an ongoing prospective
cohort study on pregnancy-related pelvic girdle pain. In addition, pregnant
women were recruited through posters in organic food shops, anthroposoph-
ical physicians’ offices, and midwives at 10 to 14 weeks of pregnancy; these
subjects comprised the alternative recruitment group (n5 491). Recruitment
of participants took place in 2001-2003 in the south of The Netherlands.
Children of women who had provided blood samples in pregnancy and had
subsequent home visits at age 2 years (n 5 829) were candidates for home
visits at age 6 to 7 years. Spirometry was measured in 443 of these children.
Genotypes were obtained from 1572 children from KOALA after exclusion of
71 children from non-Dutch mothers. Complete data on genotypes and
spirometry were available from 366 children.
Study population: ALSPAC
ALSPAC is a longitudinal, population-based birth cohort study that
recruited pregnant women residing in Avon, United Kingdom, with expected
dates of delivery from April 1, 1991, to December 31, 1992. The study
methodology has been described in detail previously.E1 Ethical approval was
obtained from the ALSPAC Law and Ethics Committee and the local research
ethics committees. Further details of the ALSPAC study are available at:
http://www.bristol.ac.uk/alspac.
TEWwas defined at 6, 18, 42 and 69 months after birth based on responses
to the following question: ‘‘In the past 12 (6 for first questionnaire) months has
(your child) had wheezing/wheezing with whistling on the chest?’’
Genotyping in PIAMA and KOALA
Genotyping in PIAMA and KOALAwas performed by means of compet-
itive allele-specific PCR with KASPar genotyping chemistry (K-Biosciences,
Herts, United Kingdom). The genotype frequencies did not deviate signifi-
cantly from Hardy-Weinberg equilibrium (P < .002).
Genotyping in ALSPAC
Genotyping was carried out at 2 different centers (the Wellcome Trust
Sanger Centre, Cambridge, United Kingdom, and Laboratory Corporation of
America, Burlington, NC) by using the Illumina HumanHap 550 array
(Illumina, San Diego, Calif). Subjects were excluded on the basis of the
following: sex mismatches, minimal or excessive heterozygosity, dispropor-
tionate levels of individual missingness (>3%), cryptic relatedness measured
as a proportion of identity by descent (IBD > 0.1), and insufficient sample
replication (IBD < 0.8). The remaining subjects were assessed for evidence ofpopulation stratification by using multidimensional scaling analysis and
compared with HapMap II (release 22) European descent (CEU), Han
Chinese, Japanese, and Yoruba reference populations; all subjects with non-
European ancestry were removed. SNPs with a minor allele frequency of less
than 1%, a call rate of less than 95%, or evidence for violations of Hardy-
Weinberg equilibrium (P < 5 3 1027) were removed. Autosomal genotypic
data were subsequently imputed with Markov Chain Haplotyping software
(MACH v.1.0.16, Li et alE2) and phased haplotype data from CEU subjects
(HapMap release 22, phase II NCBI B36, dbSNP 126) based on a cleaned
dataset of 8,365 subjects and 464,311 autosomal SNPs. After imputation, all
SNPs with indications of poor imputation quality (r2 < 0.30) were removed.
Lung function measurements
A Jaeger pneumotachograph (Viasys Healthcare) was used for lung
function testing in PIAMA. In ALSPAC and KOALA spirometry was
performed with the Vitalograph Spirotrac IV system (Vitalograph, Maids
Moreton, United Kingdom) and the handheld Medikro Spirostar USB
spirometer (Medikro, Kuopio, Finland), respectively, by using methods
described previously.E3,E4 The machines were calibrated every day on which
medical examinations took place. FVC and FEV1 were measured in the sitting
position while wearing a nose clip by trained personnel according to the
American Thoracic Society/European Respiratory Society guidelines.E5 For
each child, at least 3 acceptable maneuvers had to be obtained. The best results
of 3 acceptable and repeatable (FVC 6 150 mL) flow-volume curves were
accepted after post hoc quality control by a respiratory physician.
RESULTS
Main associations of outcomes with exposure in
KOALA and ALSPAC
Maternal smoking during pregnancy increased the risk of TEW
in KOALA (OR, 3.0 [95%CI, 1.5 to 5.8]; P5 .001) and ALSPAC
(OR, 1.3 [95% CI, 1.1 to 1.6]; P5 .001). Maternal smoking dur-
ing pregnancy was not significantly associated with FEV1
(23.2% [95% CI, 29.0% to 2.6%]; P 5 .28) or FVC (23.6%
[95% CI, 29.5% to 2.2%]; P 5 .22) in KOALA or ALSPAC
(FEV1: 20.62% [95% CI, 21.47% to 0.23%]; P 5 .15; FVC:
0.48% [95% CI, 20.38% to 1.34%]; P 5 .28). ETS exposure in
the vicinity of the child (KOALA) after birth was not significantly
associated with TEW or lung function levels in KOALA. In
ALSPAC parental smoking during the first year of life was signi-
ficantly associated with TEW (OR, 1.2 [95% CI, 1.0 to 1.4];
P 5 .03) but not with FEV1 (OR, 0.53% [95% CI, 21.35% to
0.29%]; P 5 .20) or FVC (OR, 0.35% [95% CI, 20.48% to
1.18%]; P 5 .41).
TABLE E1. Linkage disequilibrium (r2 values) between SNPs within loci
Gene SERPINE2 HHIP ANKH IREB2, AGPHD1, CHRNA3 TGFB1
SNP rs729631 rs1828591 rs735243 rs2568494 Rs2656069 rs1051730 rs1800469
rs6734100 0.73
rs1032295 0.55
rs9686327 0.73
rs2568494 — 0.14 0.68
rs2656069 0.14 — 0.12
rs8034191 0.75 0.13 0.89
rs6957 0.01
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TABLE E2. Association of SNPs in known COPD genes with TEW, FEV1, FVC, and FEV1/FVC ratio in the KOALA study
SNP Nearest gene Effect allele Genetic model Trait Effect (95% CI) P value
rs2571445 TNS1 T Additive TEW 0.91 (0.73 to 1.14) .42
rs6734100 SERPINE2 C Dominant FEV1 21.34 (210.7 to 8.01) .78
FVC 20.56 (29.96 to 8.85) .91
rs729631 SERPINE2 C Dominant FEV1 21.30 (27.41 to 4.81) .68
FVC 1.18 (24.92 to 7.29) .70
rs7671167 FAM13A T Recessive FEV1 2.39 (20.72 to 5.50) .13
FVC 1.76 (21.37 to 4.89) .27
rs1828591 HHIP A Additive TEW 0.98 (0.79 to 1.21) .82
rs2070600 AGER C Additive FEV1/FVC 0.32 (22.20 to 2.84) .80
rs2276109 MMP12 A Dominant FVC 5.97 (210.3 to 22.2) .47
Results are presented as ORs for TEW and as the mean difference in FEV1 or FVC percent predicted between children with and without the effect genotype.
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TABLE E3. Replication results of SNPs in COPD genes interacting with maternal smoking during pregnancy or environmental
smoke exposure in the first year of life in KOALA
SNP Nearest gene
Effect
allele
Genetic
model Trait
Effect (95% CI) of genotype on lung function (in presence or absence exposure)
Maternal smoking during pregnancy Environmental smoke in first year
Yes No P-int Yes No P-int
rs2571445 TNS1 T Recessive FEV1 1.86
(29.33 to 13.0)
20.25
(24.43 to 3.93)
.73
rs729631 SERPINE2 C Recessive FVC 1.76
(215.4 to 18.9)
23.78
(26.11 to 20.45)
.57 21.25
(29.23 to 6.73)
23.31
(26.37 to 20.25)
.64
rs1032295 HHIP T Dominant FEV1 1.90
(221.7 to 25.5)
20.01
(23.72 to 3.70)
.88
FEV1/FVC 21.39
(215.1 to 12.3)
21.69
(23.83 to 0.45)
.97
rs1828591 HHIP A Dominant FEV1 1.90
(221.9 to 25.7)
0.29
(23.53 to 4.09)
.90
FEV1/FVC 21.39
(214.9 to 12.1)
20.72
(22.87 to 21.43)
.92
rs6957 TGFB1 C Dominant FEV1 4.20
(28.89 to 17.3)
21.52
(24.39 to 1.34)
.40
FVC 22.97
(216.2 to 10.2)
21.33
(24.22 to 1.56)
.81
Results are presented as the mean difference in FEV1 or FVC percent predicted between children with and without the effect genotype.
P-int, P value interaction term.
P < .05 (boldface).
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